Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis

Nature Cell Biology

Volumn 9, Issue 5, 2007, Pages 493-505

  Sarkisian, Christopher J ^a   Keister, Blaine A ^a   Stairs, Douglas B ^a   Boxer, Robert B ^a   Moody, Susan E ^a   Chodosh, Lewis A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; PROTEIN P53; RAS PROTEIN; STEROID RECEPTOR;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST HYPERPLASIA; CELL AGING; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GROWTH INHIBITION; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; UPREGULATION;

ADP-RIBOSYLATION FACTORS; ANIMALS; CELL AGING; CELL CYCLE PROTEINS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYCYCLINE; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HYPERPLASIA; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; MUTATION; ONCOGENE PROTEIN P21(RAS); PRECANCEROUS CONDITIONS; PROMOTER REGIONS (GENETICS); PROTEIN TRANSPORT; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

MUS MUSCULUS;

EID: 34247897276     PISSN: 14657392     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncb1567     Document Type: Article

References (51)

1. Bos, J. L. ras oncogenes in human cancer: A review. Cancer Research 49, 4682-4689 (1989).
2. Hahn, W. C. et al. Creation of human tumour cells with defined genetic elements. Nature 400, 464-468 (1999).
3. Land, H., Parada, L. F. & Weinberg, R. A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304, 596-602 (1983).
4. Rangarajan, A., Hong, S. J., Gifford, A. & Weinberg, R. A. Species- and cell type-specific requirements for cellular transformation. Cancer Cell 6, 171-183 (2004).
5. Kamijo, T. et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91, 649-659 (1997).
6. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602 (1997).
7. Ben-Porath, I. & Weinberg, R. A. When cells get stressed: An integrative view of cellular senescence. J. Clin.I Invest. 113, 8-13 (2004).
8. Braig, M. et al. Oncogene-induced senescence as an initial barrier in lymphoma developent. Nature 436, 660-665 (2005).
9. Chen, Z. et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730 (2005).
10. Lazzerini Denchi, E., Attwooll, C., Pasini, D. & Helin, K. Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland. Mol. Cell Biol. 25, 2660-2672 (2005).
11. Michaloglou, C. et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-724 (2005).
12. Collado, M. et al. Senescence in premalignant tumors. Nature 436, 642 (2005).
13. Guerra, C. et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 4, 111-120 (2003).
14. Tuveson, D. A. et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5, 375-387 (2004).
15. Sewing, A., Wiseman, B., Lloyd, A. C. & Land, H. High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol. Cell. Biol. 17, 5588-5597 (1997).
16. Gunther, E. et al. A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J. 16, 283-292 (2002).
17. Hu, Q., Klippel, A., Muslin, A. J., Fantl, W. J. & Williams, L. T. Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase. Science 268, 100-102 (1995).
18. Kodaki, T. et al. The activation of phosphatidylinositol 3-kinase by Ras. Curr. Biol. 4, 798-806 (1994).
19. Shaulian, E. & Karin, M. AP-1 in cell proliferation and survival. Oncogene 20, 2390-2400 (2001).
20. Whitmarsh, A. J. & Davis, R. J. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J. Mol. Med. 74, 589-607 (1996).
21. Wolf, J. S. et al. IL (interleukin)-1α promotes nuclear factor-κB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin. Cancer Res. 7, 1812-1820 (2001).
22. D'Cruz, C. M. et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nature Med. 7, 235-239 (2001).
23. Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243-3248 (2001).
24. Johnson, L. et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410, 1111-1116 (2001).
25. Vitale-Cross, L., Amornphimoltham, P., Fisher, G., Molinolo, A. A. & Gutkind, J. S. Conditional expression of K-ras in an epithelial compartment that includes the stem cells is sufficient to promote squamous cell carcinogenesis. Cancer Res. 64, 8804-8807 (2004).
26. Palmero, I. & Serrano, M. Induction of senescence by oncogenic Ras. Methods Enzymol. 333, 247-256 (2001).
27. Shelton, D. N., Chang, E., Whittier, P. S., Choi, D. & Funk, W. D. Microarray analysis of replicative senescence. Curr. Bio.l 9 939-945 (1999).
28. Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363-9367 (1995).
29. Ferbeyre, G. et al. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev. 14, 2015-2027 (2000).
30. Pearson, M. et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406, 207-210 (2000).
31. Nararita, M. et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113, 703-716 (2003).
32. Ferbeyre, G. et al. Oncogenic ras and p53 cooperate to induce cellular senescence. Mol. Cell. Biol. 22, 3497-3508 (2002).
33. Lin, A. W. & Lowe, S. W. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Proc. Natl Acad. Sci. USA 98, 5025-5030 (2001).
34. Schmitt, C. A. et al. A senescence program controlled by p53 and p16(INK4a) contributes to the outcome of cancer therapy. Cell 109, 335-346 (2002).
35. Welm, B. E. et al. Sca-1(pos) cells in the mouse mammary gland represent an enriched progenitor cell population. Dev.l Biol. 245, 42-56 (2002).
36. Fujita, M., Kiyono, T., Hayashi, Y. & Ishibashi, M. hCDC47, a human member of the MCM family. Dissociation of the nucleus-bound form during S phase. J. Biol. Chem. 271, 4349-4354 (1996).
37. Stoeber, K. et al. DNA replication licensing and human cell proliferation. J. Cell Sci. 114, 2027-2041 (2001).
38. Sharpless, N. E. et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413, 86-91 (2001).
39. Jang, J. W., Boxer, R. B. & Chodosh, L. A. Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis. Mol. Cell. Biol. 26, 8109-8121 (2006).
40. Imagawa, W., Yang, J., Guzman, R. & Nandi, S. in The Physiology of Reproduction (eds. Knobil, E. & Neil, J. D.; Raven Press, New York, 1994).
41. Finney, R. E. & Bishop, J. M. Predisposition to neoplastic transformation caused by gene replacement of H-ras1. Science 260 1524-1527 (1993).
42. Aguirre, A. J. et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 17, 3112-3126 (2003).
43. Okamura, M. et al. Gene expression analysis of urethane-induced lung tumors in ras H2 mice. Toxicology 217, 129-138 (2006).
44. Quintanilla, M., Brown, K., Ramsden, M. & Balmain, A. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 322, 78-80 (1986).
45. Algarra, I., Perez, M., Serrano, M. J., Garrido, F. & Gaforio, J. J. c-K-ras overexpression is characteristic for metastases derived from a methylcholanthrene-induced fibrosarcoma. Invasion Metastasis 18 261-70 (1998).
46. Bos, J. L. The ras gene family and human carcinogenesis. Mutat. Res. 195, 255-271 (1988).
47. Johnson, S. M. et al. RAS is regulated by the let-7 microRNA family. Cell 120, 635-647 (2005).
48. Chin, L. et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400, 468-472 (1999).
49. Moody, S. et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2, 451-461 (2002).
50. Stairs, D. B., Notarfrancesco, K. L. & Chodosh, L. A. The serine/ threonine kinase, Krct, affects endbud morphogenesis during murine mammary gland development. Transgenic Res. 14, 919-940 (2005).
51. Sarkisian, C. J., Master, S. R., Huber, L. J., He, S. I. & Chodosh, L. A. Analysis of murine Brca2 reveals conservation of protein-protein interactions but differences in nuclear localization signals. J. Biol. Chem. 276, 37640-37648 (2001).